Figure 3.

Recombinant human RNASE4 protein potently restores the oncogenic properties mitigated by RNASE4 knockdown in DBTRG-05MG cells. Cellular migration (A) and invasion (B) abilities of DBTRG-05MG cells, significantly reduced by RNASE4 knockdown, were restored upon treatment with recombinant human RNASE4 protein (hRNASE4) for 16 h (**P<0.01). (C) Oncosphere formation in RNASE4-KD cells was restored by treatment with hRNASE4 (oncosphere culture medium replaced every three days with or without hRNASE4 supplement), demonstrating the extracellular effects of RNASE4 on this oncogenic property. (D) Cellular viability following TMZ treatment for 3 days in control or RNASE4-knockdown DBTRG-05MG cells, with or without recombinant human RNASE4 treatment, was assessed. P<0.05. Data are mean ± SEM from at least three independent experiments.